Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer is warning physicians that it expects a new shortage of Bicillin L-A, a long-acting penicillin injection that is currently the single recommended treatment for syphilis during pregnancy, CNN ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Shares of Johnson & Johnson climbed 4.5% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for the biggest one-day gain since they rallied 4.6% on May 1, 2024.

Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

Pfizer’s trading volume surged to $13.51 billion, more than doubling from the prior day. Despite the impressive spike in ...

This was the stock's third consecutive day of losses.

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented investors. Increases in dividend per share (DPS) greatly allow companies to ...